# A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

> **NCT06887803** · PHASE1,PHASE2 · RECRUITING · sponsor: **iOnctura** · enrollment: 26 (estimated)

## Conditions studied

- Myelofibrosis (MF)

## Interventions

- **DRUG:** Roginolisib

## Key facts

- **NCT ID:** NCT06887803
- **Lead sponsor:** iOnctura
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2028-03
- **Final completion:** 2028-07
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887803, "A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06887803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*